DU109CZ
Brachytherapy Ovary to None with Californium 252 (Cf-252), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | U Female Reproductive System |
| Operation | 1 Brachytherapy |
| Body Part | 0 Ovary |
| Approach | 9 High Dose Rate (HDR) |
| Device | C Californium 252 (Cf-252) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for the female reproductive system involves placing a radioactive source directly inside or immediately adjacent to reproductive tissue - most commonly the cervix or uterus, and sometimes the vagina - so radiation is delivered from within the body rather than through it. Applicators are inserted, often under anesthesia and with imaging or exam guidance, and then loaded with a radioactive source for a defined period before removal.
This is a cornerstone of curative treatment for cervical cancer, typically given as a boost after a course of external beam radiation to concentrate additional dose directly into the tumor bed while limiting exposure to the bladder and rectum nearby. It's also used for some endometrial and vaginal cancers, particularly to treat the vaginal cuff after surgery or to manage disease confined to a small, accessible area.
Because the source sits in direct contact with or very near the target tissue, brachytherapy can deliver a dose intensity that external beams alone can't safely achieve, which is why it plays such a central role in gynecologic cancer treatment protocols despite requiring more invasive placement than beam therapy.
Anatomy & Axis Detail
Ovary
Brachytherapy applied to the ovary involves placing a radioactive source in close proximity to or within ovarian tissue, an approach used far less often than external beam given the ovary's small size and mobility within the pelvis. When used, it is typically reserved for localized recurrent disease or as a boost to a residual mass after prior treatment, allowing a high local dose while sharply limiting exposure to nearby bowel, bladder, and the contralateral ovary. Because the ovary lacks the fixed cavity or canal that facilitates source placement in organs like the cervix or uterus, brachytherapy here often requires surgical or image-guided placement of applicators, and documentation should specify how the source was positioned relative to the target tissue.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Californium 252 (Cf-252)
Californium-252 is a neutron-emitting source rather than a gamma or beta emitter, used in specialized brachytherapy for radioresistant tumors such as certain cervical or head and neck cancers where neutrons' higher relative biological effectiveness offers an advantage. It is far less commonly used than the gamma-emitting seed isotopes and is documented separately because its neutron output changes tissue interaction and shielding requirements.
Coding & Documentation
The documentation needs to identify the specific structure treated - cervix, uterus, vagina - and confirm that a radioactive source was placed in or against that tissue, distinguishing the procedure from external beam radiation aimed at the same organs. Operative and radiation oncology notes describing applicator insertion (such as a tandem and ovoid or ring applicator) followed by source loading support this code, and coders should verify whether the applicator placement and the radiation delivery were documented as one episode or need separate capture per facility convention.
A frequent error is coding the applicator insertion procedure without also capturing the radiation delivery itself, or the reverse, when documentation describes them as distinct steps. Coders should also confirm the correct body part when the applicator spans multiple structures, since a tandem and ovoid system treats the uterus and vagina together but the primary target documented by the physician should guide code selection.